en · de · es · fr · pt
assay-notes.peptides3626.com › Guide › Identity And Molecular Background — What the Evidence Shows

Identity And Molecular Background — What the Evidence Shows

By Editorial Desk · published 2025-08-06 · last reviewed 2025-09-02 · Guide

The short version of lyophilized powder fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2025-09-02 and is reviewed periodically as new material appears.

Identity and Molecular Background

Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.

The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.

Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.

Handling, Storage, and Analysis

Lyophilized material is generally held at reduced temperature to slow degradation, and storage at minus twenty degrees Celsius or lower is common practice for long-term retention. Short-term working portions are often kept between two and eight degrees Celsius. Once dissolved, the peptide is less stable than the dry powder, and repeated freeze-thaw cycles are associated with loss of material and with aggregate formation. Vials are usually allowed to reach room temperature before opening so that condensation does not introduce moisture, and solutions are protected from light where practical.

Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography, which separates the peptide from closely related impurities and from truncated or oxidized variants. Mass spectrometry supplies the molecular mass and confirms the expected sequence length, while amino acid analysis can be used to check composition. Because the molecule has no chromophore beyond the peptide backbone, ultraviolet detection is typically performed at a low wavelength, where baseline interference from solvents and buffers is a practical concern. Water content and counter-ion content are often reported alongside purity.

Thymosin-alpha-1 at a glance

PropertyValueNotes
Molecular formulaC129H215N33O55Calculated for the acetylated 28-residue peptide
AppearanceWhite to off-white powderLyophilized solid recovered from aqueous buffer
SolubilityFreely soluble in waterTypically dissolved in water or buffer before use
Typical storage-20 C or below, desiccatedProtect from light and avoid repeated freeze-thaw cycles
Identity testingReverse-phase HPLC with mass spectrometryRetention time and measured mass confirm the sequence

Storage Handling And Laboratory Analysis

Recommended storage for the dry powder is a freezer near minus twenty degrees Celsius, kept desiccated and away from light. Once dissolved, the peptide is less stable and is usually held at two to eight degrees Celsius for short intervals or frozen for longer storage. Stability studies focus on the acetylated terminus and the disulfide linkage because those features define the intact molecule. Common degradation routes include cysteine oxidation, deamidation of asparagine or glutamine side chains, and slow formation of higher-molecular-weight species.

Identity and purity are usually checked by reverse-phase high-performance liquid chromatography, which separates the intact chain from truncated products, together with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion and amino acid analysis add sequence-level evidence. Release testing also covers water content, residual solvents, and counter-ions, all of which influence measured mass and stability. Related-peptide limits are commonly expressed as a percentage of total peak area, with individual unspecified impurities held below a lower threshold.

The lyophilized peptide is a white to off-white powder that dissolves freely in water and in aqueous buffers near neutral pH. Because the molecule carries a net negative charge under physiological conditions, saline and phosphate solutions are the usual vehicles, while strongly acidic media are avoided. Stock solutions are commonly divided into small aliquots so that repeated freezing and thawing can be limited, since cycling may encourage aggregation. Solubility in organic solvents is poor and those solvents are seldom used as primary diluents.

Related pages on this site

Analytical Methods and Storage Stability

Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.

The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.

Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.

Storage, Handling and Analytical Verification

Laboratory supplies of the peptide usually arrive as a lyophilized powder in sealed vials. The powder is hygroscopic, so a vial should be allowed to reach room temperature before it is opened to prevent condensation on the contents. Weighing and transfer are best performed in a low-humidity environment with clean tools. Once dissolved, the solution should be mixed gently rather than vortexed, because foaming and shear can reduce recovery of the peptide.

Storage recommendations center on low temperature, dryness, and protection from repeated freezing and thawing. The intact powder is commonly held at 20 degrees below zero Celsius or colder, while a working solution is divided into single-use aliquots to limit freeze-thaw cycles. Buffered saline or phosphate-buffered saline at neutral pH is frequently used as a diluent. Light sensitivity is not well documented, yet amber vials or foil wrapping are common practice for long-term storage of peptide stocks.

Identity and purity are assessed with a small set of standard peptide methods. Reversed-phase high-performance liquid chromatography separates the main peak from truncated or oxidized species, and its area percentage is the usual purity measure. Mass spectrometry confirms the observed molecular mass against the expected value, while amino acid analysis or peptide mapping checks composition and sequence. Specifications for research-grade material are often stated as 95 percent or higher, though the exact limit depends on the supplier and the intended use.

Stability, Storage, and Analysis

Routine handling calls for storage of the lyophilized powder at refrigerated temperatures, away from light, in a sealed container. Working solutions are often prepared in sterile water or buffer and kept cold between uses. Repeated freeze-thaw cycles are generally avoided because they can promote aggregation and loss of material. Laboratories usually record lot number, reconstitution date, and storage conditions so that any change in behavior can be traced to a specific preparation.

Reverse-phase high-performance liquid chromatography is the standard technique for assessing purity and concentration, because the peptide's hydrophobicity allows clean separation from related impurities. Mass spectrometry confirms molecular identity and detects sequence errors or truncations. Amino acid analysis and peptide mapping supply additional structural confirmation when required. Chromatographic purity values reported on certificates of analysis describe the proportion of the main peak and do not by themselves establish biological activity.

Supporting material

Today, it is considered that GBS pigment (granadaene) and hemolysin are identical or closely related molecules. Sialic acid is a notable virulence factor in S. agalactiae despite being found normally in humans and many other animals. By expressing an unusually high amount of sialic acid on the bacterial cell surface, S. agalactiae can subvert the innate immune system, convincing leukocytes that the bacteria are human cells.

Furthermore, Peukert argued that völkisch racism was part of a male backlash against women's emancipation, and was a way of asserting control over women's bodies, which were viewed in a certain sense as public property since women had the duty of bearing the next generation that would pass on the "healthy genes". Peukert maintained that as the bearers of the next generation of Germans that Nazi social policies fell especially heavily upon German women. Peukert argued that for volksgenossinnen (female "national comrades"), any hint of non-conformity and the "pleasures of refusal" in not playing their designated role within the volksgemeinschaft as the bearers of the next generation of soldiers could expect harsh punishments such as sterilization, incarceration in a concentration camp or for extreme case vernichtung ("extermination"). Peukert wrote that "after 1933 any critical public discussion and any critique of racism in the human sciences from amongst the ranks of the experts was eliminated: from then on, the protective...instances of the Rechtsstaat (legal state) no longer stood between the racist perpetrators and their victims; from then on, the dictatorial state put itself solely on the side of racism". Peukert argued that all of the National Socialist social policies such as natalist policies that relentlessly pressured Aryan women to have more and children were all part of the same effort to strengthen the volksgemeinschaft.

== Metabolome databases == Because an organism's metabolome is largely defined by its genome, different species will have different metabolomes. Indeed, the fact that the metabolome of a tomato is different from the metabolome of an apple is the reason why these two fruits taste so different. Furthermore, different tissues, different organs and biofluids associated with those organs and tissues can also have distinctly different metabolomes. The fact that different organisms and different tissues/biofluids have such different metabolomes has led to the development of a number of organism-specific and biofluid-specific metabolome databases. Some of the better known metabolome databases include the Human Metabolome Database or HMDB, the Yeast Metabolome Database or YMDB, the E. coli Metabolome Database or ECMDB, the Arabidopsis metabolome database or AraCyc as well as the Urine Metabolome Database, the Cerebrospinal Fluid (CSF) Metabolome Database and the Serum Metabolome Database. The latter three databases are specific to human biofluids. A number of very popular general metabolite databases also exist including KEGG, MetaboLights, the Golm Metabolome Database, MetaCyc, LipidMaps and Metlin. Metabolome databases can be distinguished from metabolite databases in that metabolite databases contain lightly annotated or synoptic metabolite data from multiple organisms while metabolome databases contain richly detailed and heavily referenced chemical, pathway, spectral and metabolite concentration data for specific organisms.

Sources: en.wikipedia.org

Supporting material

Primary hyperlipidemia, alone or with a statin Mixed hyperlipidemia, in combination with fenofibrate Homozygous familial hypercholesterolemia, in combination with specific statins Homozygous sitosterolemia A 2018 review found that ezetimibe used as sole treatment slightly lowered plasma levels of lipoprotein(a), but the effect was not large enough to be important. Ezetimibe improves the non-alcoholic fatty liver disease activity score but the available evidence indicates it does not improve outcomes of hepatic steatosis.

By August, eight of the nine republics, except Ukraine, had approved the draft of the new Treaty with some conditions. Ukraine did not agree on the terms of the Treaty. In the simultaneous Ukrainian republican referendum on 17 March, the majority of residents of Ukraine supported joining the Union on the basis of the 16 July 1990 Declaration of State Sovereignty of Ukraine. In addition, most of autonomous republics expressed the desire to raise their status and to be a party to the new Soviet treaty and declared sovereignty and self-promotion to republics during the parade of sovereignties in the months following the initial proposal from July 1990. Most of them participated in the Novo-Ogaryovo process to draft the treaty, and the status of former autonomous republics was a major point of contention among participants. On July 12, 1991, the Supreme Soviet passed the resolution "About the draft treaty on Union of Sovereign States" to state its stance on the matter that each of "the subjects of the federation, including both the sovereign states - the republics - and the republics incorporated within them on a treaty or constitutional basis" "possesses the right to sign the text of the Union Treaty". As a compromise, the final draft of the treaty allowed a state to join the Union as a part of another state, but only the nine republics were invited to sign it at Novo-Ogaryovo on July 23. Following the August coup, the New Union Treaty was further reformed into the Commonwealth of Independent States.

Acute myocardial infarction (heart attack) Heart failure (left ventricular systolic dysfunction) Kidney complications of diabetes mellitus (diabetic nephropathy) by means of decreasing the blood pressure and preventing glomerular hyperfiltration injury In treating high blood pressure, ACE inhibitors are a first-line initial drug choice. Age, frailty, and race can influence treatment choices and it is common to need more than one drug to obtain the desired improvement. All ACE inhibitors but enalapril, which can be given intravenously, are administered orally. Each one has different strengths with different starting dosages. Dosage should be adjusted according to the clinical response. Most ACE inhibitors can be dosed once daily with the exception of captopril. ACE inhibitors possess many common characteristics with another class of cardiovascular drugs, angiotensin II receptor antagonists, which are often used when patients are intolerant of the adverse effects produced by ACE inhibitors. ACE inhibitors do not completely prevent the formation of angiotensin II, as blockage is dose-dependent, so angiotensin II receptor antagonists may be useful because they act to prevent the action of angiotensin II at the AT1 receptor, leaving AT2 receptor unblocked; the latter may have consequences needing further study. There are fixed-dose combination drugs, such as ACE inhibitor and thiazide combinations. ACE inhibitors have also been used in chronic kidney failure and kidney involvement in systemic sclerosis (hardening of tissues, as scleroderma renal crisis).

Like PAH metabolites, acrolein is also an electrophilic alkylating agent and permanently binds to the DNA base guanine, by a conjugate addition followed by cyclization into a hemiaminal. The acrolein-guanine adduct induces mutations during DNA copying and thus causes cancers in a manner similar to PAHs. However, acrolein is 1000 times more abundant than PAHs in cigarette smoke and can react without metabolic activation. Acrolein has been shown to be a mutagen and carcinogen in human cells. The carcinogenicity of acrolein has been difficult to study by animal experimentation, because it has such a toxicity that it tends to kill the animals before they develop cancer. Generally, compounds able to react by conjugate addition as electrophiles (so-called Michael acceptors after the Michael reaction) are toxic and carcinogenic, because they can permanently alkylate DNA, similarly to mustard gas or aflatoxin. Acrolein is only one of them present in cigarette smoke; for example, crotonaldehyde has been found in cigarette smoke. Michael acceptors also contribute to the chronic inflammation present in diseases brought about by smoking. Nitrosamines are a group of carcinogenic compounds found in cigarette smoke but not in uncured tobacco leaves. Nitrosamines form on flue-cured tobacco leaves during the curing process through a chemical reaction between nicotine and other compounds contained in the uncured leaf and various oxides of nitrogen found in all combustion gases. Switching to indirect fire curing has been shown to reduce nitrosamine levels to less than 0.1 parts per million.

Sources: en.wikipedia.org

Frequently asked questions

What is thymosin alpha 1?

It is a 28-amino-acid peptide originally purified from a bovine thymic extract and later produced synthetically. It is studied mainly for its effects on immune cell function.

Is thymosin alpha 1 the same as thymosin beta 4?

No. The two peptides share part of a name but differ in length, sequence, and net charge. Literature searches that treat them as one compound return misleading results.

How is the peptide obtained for laboratory work?

Solid-phase peptide synthesis is the usual route, and recombinant expression has also been described. Both approaches produce material matching the natural sequence.

How should the dry powder be stored?

Cool storage below freezing is usual for long-term retention, with a desiccant and protection from light. Portions are often split before first use to avoid repeated handling.

Network